Maxime Verhoeven

34 Chapter 2 15. Horslev-Petersen, K. et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind trial. Ann. Rheum. Dis. 73 , 654–661 (2014). 16. Keystone, E. C. et al. Time to achieve moderate/low disease activity and remission in RA patients on baricitinib compared to adalimumab, methotrexate, and placebo. Arthritis Rheumatol. 69 , (2017). 17. Keystone, E. C. et al. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open 3 , (2017). 18. Kirchgesner, T. et al. Evaluation of MRI RAMRIS score and clinical response in patients with ACPA positive undifferentiated arthritistreated with infliximab versus placebo. Ann. Rheum. Dis. 77 , 1764 (2018). 19. Nam, J. L. et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann. Rheum. Dis. 73 , 1027–1036 (2014). 20. Smolen, J. S. et al. Attainment and characteristics of clinical remission according to the new ACR- EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the abatacept study to gauge remission and joint damage progression inmethotrexate (MTX)-naive patients with early erosive rheumatoid arthritis (AGREE). Arthritis Res. Ther. 17 , 157 (2015). 21. Stamm, T. A. et al. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Res. Ther. 20 , 174 (2018). 22. Takeuchi, T. et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann. Rheum. Dis. 73 , 536–543 (2014). 23. Brunekreef, T. & Bernelot Moens, H. Remission induction with methotrexate step-up therapy versus combination of hydroxychloroquine, methotrexate and triamcinolone: 3 year results. Ann. Rheum. Dis. 76 , 147–148 (2017). 24. Ma, M. H. Y., Scott, I. C., Dahanayake, C., Cope, A. P. & Scott, D. L. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen. J. Rheumatol. 41 , 1298–1303 (2014). 25. Rannio, T. et al. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort. Scand. J. Rheumatol. 46 , 425–431 (2017). 26. Steunebrink, L. M. M. et al. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res. Ther. 18 , 60 (2016). 27. Akdemir, G. et al. Comparison between low disease activity or das remission as treatment target in patients with early active rheumatoid arthritis. RMD Open 4 , (2018). 28. de Jong, P. H. et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy: 1-year data of the tREACH trial. Ann. Rheum. Dis. 73 , 1331–1339 (2014). 29. Nam, J. L. et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment- naive, rheumatoid arthritis (the IDEA study). Ann. Rheum. Dis. 73 , 75–85 (2014). 30. Stouten, V. et al. Sustained effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) for early rheumatoid arthritis in a treat-to-target setting: 2-year results of the carera trial. Ann. Rheum. Dis. 76 , 147 (2017).